Jiangsu Yuyue Medical Equipment & Supply (002223) Q2 2025 earnings summary

Executive summary

• Achieved revenue of ¥4.66 billion, up 8.16% year-over-year, with net profit attributable to shareholders of ¥1.20 billion, up 7.37% year-over-year.

• Operating cash flow increased 15.13% year-over-year to ¥1.17 billion.

• Main business segments include respiratory therapy, blood glucose management & POCT, home health monitoring, clinical & rehabilitation devices, and emergency solutions.

• Overseas revenue grew 26.63% year-over-year, now 13.03% of total revenue.

Financial highlights

• Gross margin reached 50.37%, up 0.37 percentage points year-over-year.

• R&D expenses rose 9.44% to ¥295 million, representing 6.33% of revenue.

• Total assets at period end were ¥16.53 billion, up 5.64% from year-end 2024.

• Net assets attributable to shareholders increased 6.10% to ¥13.30 billion.

• Adjusted net profit (excluding non-recurring items) was ¥913.7 million, down 5.22% year-over-year.

Outlook and guidance

• Focus remains on high-end, high-margin medical devices and global market expansion.

• Continued investment in AI, digitalization, and wearable medical technology.

• Plans to further strengthen R&D, sales, and international teams.